Behcet’s disease

Behcet’s disease is a rare, chronic, systemic vasculitis that can affect multiple organ systems including the skin, mucous membranes, eyes, joints, and vascular structures. It is more common in regions along the ancient Silk Road and presents with recurrent inflammatory episodes. Early recognition and management are essential to prevent severe complications.

Definition and Pathophysiology

Behcet’s disease is defined as a chronic, relapsing vasculitis characterized by recurrent oral and genital ulcers, ocular inflammation, and systemic manifestations. The underlying pathophysiology involves an abnormal immune response leading to inflammation of blood vessels of all sizes.

• Autoimmune mechanisms: Dysregulated immune activation with neutrophil hyperactivity and T-cell mediated inflammation.
• Genetic predisposition: Strong association with HLA-B51 allele, increasing susceptibility to disease.
• Role of environmental triggers and infectious agents: Bacterial or viral infections may trigger disease onset or exacerbate flares.
• Vascular inflammation and multi-system involvement: Affects arteries and veins of all calibers, leading to mucocutaneous, ocular, neurological, gastrointestinal, and vascular complications.

Etiology and Risk Factors

The exact cause of Behcet’s disease is unknown, but it is thought to result from an interplay between genetic susceptibility and environmental triggers. Several risk factors have been identified that influence disease development and severity.

• Genetic factors:
  • HLA-B51 positivity
  • Familial clustering suggesting inherited susceptibility
• Environmental factors: Geographic prevalence is highest in Turkey, Iran, and East Asia.
• Infectious triggers: Streptococcal and viral infections may precipitate disease onset or flares.
• Demographic factors: Typically affects adults aged 20-40 years, with slightly higher prevalence in males in certain populations.

Clinical Features

Behcet’s disease manifests with a wide range of clinical features due to its systemic vasculitis, often presenting with recurrent inflammatory episodes affecting multiple organ systems.

• Mucocutaneous manifestations:
  • Recurrent oral ulcers, often painful and aphthous
  • Genital ulcers with scarring in some cases
  • Skin lesions such as erythema nodosum, papulopustular eruptions, and acneiform lesions
• Ocular involvement:
  • Anterior or posterior uveitis
  • Retinal vasculitis
  • Potential for vision loss if untreated
• Musculoskeletal involvement:
  • Arthralgia and non-erosive arthritis
  • Joint swelling and tenderness, commonly in knees, ankles, and wrists
• Neurological manifestations:
  • CNS involvement including headaches, confusion, and stroke-like symptoms
  • Neuro-Behcet’s disease affecting brainstem and cerebral hemispheres
• Gastrointestinal involvement:
  • Abdominal pain, diarrhea, and gastrointestinal ulcers mimicking inflammatory bowel disease
• Vascular involvement:
  • Venous thrombosis including deep vein thrombosis
  • Arterial aneurysms and thromboses
• Other systemic features: Fever, fatigue, and malaise during disease flares

Diagnostic Evaluation

Diagnosis of Behcet’s disease is primarily clinical, supported by laboratory tests and imaging to identify systemic involvement and exclude other conditions.

Clinical Criteria

• International Study Group (ISG) criteria for Behcet’s disease
• International Criteria for Behcet’s Disease (ICBD) incorporating point-based scoring of symptoms

Laboratory Investigations

• Inflammatory markers such as ESR and CRP to assess disease activity
• HLA-B51 typing for genetic susceptibility
• Exclusion of infectious or autoimmune mimics through serology and cultures

Imaging Studies

• Ocular imaging including fundoscopy and fluorescein angiography
• MRI or CT for neurological involvement
• Ultrasound or angiography to evaluate vascular lesions

Differential Diagnosis

Behcet’s disease shares features with several other systemic and autoimmune disorders, making differential diagnosis essential to ensure proper treatment.

• Systemic lupus erythematosus: Can present with oral ulcers, arthritis, and vascular involvement, but typically includes autoantibodies such as ANA and dsDNA.
• Inflammatory bowel disease: Crohn’s disease and ulcerative colitis may mimic gastrointestinal and mucocutaneous manifestations.
• Other vasculitides:
  • Polyarteritis nodosa
  • Giant cell arteritis
  • Granulomatosis with polyangiitis
• Recurrent aphthous stomatitis: Isolated oral ulcers without systemic involvement.

Management and Treatment

Management of Behcet’s disease requires a multidisciplinary approach focused on reducing inflammation, controlling symptoms, and preventing organ damage.

Pharmacologic Therapy

• Corticosteroids for acute flares and systemic inflammation
• Immunosuppressive agents such as azathioprine, cyclophosphamide, and cyclosporine for moderate to severe disease
• Biologic therapies including TNF inhibitors and interferon-alpha for refractory cases
• Colchicine for mucocutaneous and joint manifestations

Supportive and Symptomatic Management

• Pain control and local care for oral and genital ulcers
• Ophthalmologic interventions to prevent vision loss
• Monitoring and management of thrombotic and vascular complications

Multidisciplinary Approach

• Collaboration among rheumatology, ophthalmology, neurology, gastroenterology, and dermatology
• Regular follow-up to monitor disease activity and treatment response

Prognosis and Complications

The prognosis of Behcet’s disease varies depending on the extent of systemic involvement and the timeliness of treatment. While mucocutaneous symptoms are generally manageable, organ-threatening complications require prompt intervention.

• Impact on life expectancy: Generally normal for mild disease but may be reduced in patients with severe vascular, neurological, or ocular involvement.
• Ocular complications: Recurrent uveitis can lead to vision loss or blindness if untreated.
• Neurological complications: CNS involvement can result in stroke, cognitive deficits, or cranial neuropathies.
• Vascular complications: Deep vein thrombosis, arterial aneurysms, and pulmonary embolism are significant risks.
• Other systemic complications: Gastrointestinal bleeding, arthritis-related joint damage, and chronic pain.

Prevention and Patient Education

Although Behcet’s disease cannot be prevented, patient education and early intervention are essential to reduce the risk of severe complications and improve quality of life.

• Early recognition of symptoms and prompt medical consultation
• Education on adherence to prescribed pharmacologic therapies
• Regular monitoring for ocular, neurological, and vascular complications
• Lifestyle modifications to reduce infection risk and manage inflammation
• Importance of multidisciplinary follow-up to optimize disease control and prevent organ damage

References

1. Hatemi G, Seyahi E, Fresko I, et al. Behçet’s syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14(2):107-119.
2. International Team for the Revision of the International Criteria for Behçet’s Disease (ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries. J Eur Acad Dermatol Venereol. 2014;28(3):338-347.
3. Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome. Curr Opin Rheumatol. 2012;24(1):1-5.
4. Fresko I, Hamuryudan V, Yurdakul S, et al. Behçet’s disease: epidemiology, clinical features, and diagnostic criteria. Rheumatol Int. 2003;23(5):197-204.
5. Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet. 1990;335(8697):1078-1080.
6. Leccese P, Rizzo C, Talarico R, et al. Clinical manifestations of Behçet’s disease. Clin Exp Rheumatol. 2016;34 Suppl 102(4):S4-S12.
7. de Menthon M, Lavalley MP, Maldini C, et al. HLA-B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61(10):1287-1296.
8. Calamia KT, Wilson FC, Icen M, et al. Epidemiology and clinical characteristics of Behçet’s disease in the United States: a population-based study. Arthritis Rheum. 2009;61(5):600-608.
9. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77(6):808-818.